Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. by Venkataramanan, R et al.
--- ---":-·t=---~---D--~---
Pharmacokinetics of FK 506 Following Oral Administration: A 
comparison of FK 506 and Cyclosporine 
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FK 506 is currently used as the primary immunosup-pressant in. over 800 organ tra~splant pati~nts at ~e 
University of Pittsburgh. FK 506 IS a macrolide and IS 
chemically very different from any other immunosuppres-
sive drug used currently in transplant patients. Howe .. cr, 
FK 506 is very similar to cyclosporine (Cy A) in a numt-er 
of physicochemical properties and its mechanism of action 
(Table 1).1.2 The objective of the present study is to 
determine the pharmacokinetics of FK 506 after oral 
administration. to compare its kinetic properties 1oI.ith 
erA. and to discuss the clinical relevance of the differ-
ences in the kinetic properties. 
DOSAGE FORM 
FK 506 was administered to patients as an IV infusion over 
2 to 4 hours or as a continuous infusion over 24 hours. For 
oral administration. a hard gelatin capsule containing a 
20% solid dispersion of FK 506 in hydroxy propyl methyl 
cellulose and HCHO 60 was used. 
DRUG ANAL YSIS 
For the kinetic study, multiple blood samples were ob-
tained over a dosing interval of 12 or 24 hours. Blood 
samples were incubated at 37°C for 1 hour and plasma was 
separated at 37°C. FK 506 concentration in plasma was 
analyzed by a monoclonal antibody (MAb) based enzyme-
linked immunosorbent assay (ELISA) as des...ibed 
earlier.3 
PHARMACOKINETICS 
The pharmacokinetics of FK 506 after IV administration 
has previously been reported."' Similar pharmacoLnetic 
parameters were also obtained in the present stud). Fol-
lowing IV infusion, FK 506 concentration declines rapidly 
initially and at a slower rate after reaching distnootion 
Table 1. Physicochemical Properties of FK 506 and CyA 
Source 
Molecular weight 
POOI1y soluble 
Very soluble 
ToIypocIacium inflatum 
(fungal byproduct) 
1202 
Waler, hexane 
Elhanol. methanol. 
propytene glycol. 
polyethylene glycol 
Streptomyces lSuku-
baensis (Ulgal 
byproducli 
822 
Water. hexane 
Ethanol. ndlanoI, 
pf"OJ¥ene glycol, 
~glycol 
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Fig 1. FK 506 plasma concentration vs time curve after 3 mg IV 
(el and 9 mg oral (_) administration in a liver transplant paDen!. 
equilibrium (Fig I). The half-life ranges from 3.5 to 40.5 
hours with a mean value of 11.3 hours (n = 31). The plasma 
clearance of FK 506 ranges from 5.8-103 mL'min'kg, 
indicating the drug to be a high clearance drug. Higher 
half-lives and lower clearance values were observed in 
patients with impaired hepatic function. The large volume 
of distribution (10,751) indicates extensive distribution of 
the drug outside the plasma compartment. 
Pharmacokinetics of FK 506 was studied in 14 patients 
on 31 occasions after oral doses of 2 to 18 mg. F K 506 was 
absorbed fairly rapidly in most of the subjects with peak 
plasma concentrations being reached within 1 hour. How-
ever. in certain patients peak concentrations were reached 
only at 4 hours. In nearly half of the patients studied there 
was sustained plasma concentration throughout the entire 
dosing interval. This may be the result of the slow disso-
lution of FK 506 from the solid dispersion in the gastric 
fluids. The dose normalized peak plasma concentration 
ranged from 0.1 to 0.5 nglmUmg. Sufficient data were 
available to calculate oral bioavailability in 14 studies. The 
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Table 2. Pharmacoklnetlc Panllneters of eyA and FK 506 
Parameter CyA FK 506 
Atsorption 
nne to peak 2-4 h 0.5-4 h 
Extent of absorption PM"~ 25% 
[)sribution 
BoodIplasma 1-2 >4 
LJ;x>protein High Low 
lJ;:Ioprotein free plasma Low High 
"D~ume of distribution 2.501 10,751 
(plasma data) 
Einnation 
~lism >98% >98% 
UI"l"lary excretion of <2"", <2% 
.. mchanged drug 
~Kabolite excretion Biliary Biliary 
Half-life 5-12 h 4·14 h 
Clearance 10 mLmlr.kg 43 mUmin/kg 
abs..-":ute bioavailability ranged from 6% to 56% (mean, 
25CC, in transplant patients with various degrees of liver 
fuoction. 
COMPARISON OF FK 506 AND CyA 
Absorotion 
The pharmacokinetic parameters for FK 506 and CyA are 
listed in Table 2. FK 506 appears to be absorbed more 
rapidl~ than CyA; however, both compounds are absorbed 
to a si..-nilar extent. This indicates that three to four times 
higher oral doses are required, as compared with IV doses, 
to mairltain similar plasma concentration time profiles for 
both d:ugs. In a number of patients FK 506 is absorbed 
over IT'AIly hours with less fluctuations in plasma concen-
tration \'s time curve over a dosing interval. 
Di stribl.tJOn 
Both FK 506 and Cy A are highly distributed into red blood 
cells. While the blood to plasma concentrations of CyA is 
about fK~K that of FK 506 is greater than 4. Within plasma, 
Cy A is primarily associated with lipoproteins while FK 506 
is associated with lipoprotein deficient plasma. 5 
EliminatIOn 
Cy A and FK 506 are primarily eliminated by hepatic 
metabolism.4.6 Most of the metabolites are excreted in the 
bile. Thes.e observations indicate that hepatic dysfunction 
"ill impair the elimination of these drugs.' The elimination 
of the drug is also susceptible to induction and inhibition of 
hepatic drug metabolizing enzymes. Such drugs should, 
therefore. be used with caution in patients receiving FK 
506 or C) _ .... Less than 2% of the drug is excreted in the 
urine as unchanged drug. This indicates that changes in 
renal function are not likely to affect the elimination of FK 
5068 or CyA.9 
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rig 2. FK 506 plasma concentration vs time curve in a liver 
transplant patient with open E~F and closed (.) T-tube. 
EFFECT OF CERTAIN CLINICAL EVENTS 
ON KINETICS 
T-Tube Clamping 
T-tube clamping is well known to increase eyA concen-
trations in liver transplant patients. 10 Since very little CyA 
is excreted unchanged in the bile, enterohepatic circulation 
is not responsible for this observation. Increased availabil-
ity of bile facilitates CyA absorption resulting from solu-
bilization of CyA. On the other hand, clamping of the 
T-tube does not alter the area under the plasma concen-
tration vs time curve for FK 506' (Fig 2). This indicates 
that bile is not as essential for FK 506 absorption as it is for 
CyA absorption. Therefore, no dosing changes are indi-
cated when the I-tube is clamped in liver transplant 
patients (Table 3). 
Impaired Liver Function 
The oral absorption of CyA is decreased in patients with 
liver disease. 9 ln dogs with experimentally induced chole-
stasis Cy A absorption is significantly reduced II (Fig 3). 
Liver dysfunction does not decrease the oral absorption of 
FK 506 in liver transplant patients. 7 In dogs with experi· 
mentally induced cholestasis the oral bioavailability of FK 
506 is in fact increased as compared with control dogs '2 
(Fig 3). This indicates that more FK 506 reaches systemic 
circulation in the absence of bile. Presently additional 
studies are being conducted in dogs with choledocho-
Table 3. Dosing Recommendations for Clinical Events 
CyA Fl< 506 
T-Tube Clamping Decrease No change 
Liver dysfunction 
IV Decrease Decrease 
PO IV? Increase 
Renal dysfunction No change No change 
Dialysis No change No change 
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Fig 3. Bioavailability of eyA and FK 506 in dogs before and after 
experimental liver dysfunction induced by cholestasis. 
ureterostomy to determine the effect of bile on FK 506 
absorption. Independent of the mechanism involved it is 
clear that while CyA doses have to be increased or if the 
patient has to be converted to IV CyA therapy in presence 
of hepatic dysfunction, a dose reduction is necessary for 
FK 506 under similar circumstances8 (Table 3). 
Renal Dysfunction and Dialysis 
Since very little eyA or FK 506 is excreted in the urine. no 
changes in the dosing regimen of FK 506 or Cy A is 
necessary in patients with renal impairment or patients 
undergoing dialysis (Table 3). 
Cy A and FK 506 are similar in a number of respects 
933 
such as their physicochemical and certain pharmacoki-
netic properties and mechanism of action. However. they 
are distinctly different with regards to the effect of T -tube 
clamping and the effect of bile and hepatic dysfunction on 
their aMorption. These factors must be kept in mind in any 
dosing regimen changes of these drugs in transplant pa-
tients. 
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